- Home
- CZNC vs ATYR Comparison
CZNC vs ATYR Comparison
Compare CZNC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ATYR
- Stock Information
- Founded
- CZNC 1864
- ATYR 2005
- Country
- CZNC United States
- ATYR United States
- Employees
- CZNC N/A
- ATYR N/A
- Industry
- CZNC Major Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CZNC Finance
- ATYR Health Care
- Exchange
- CZNC Nasdaq
- ATYR Nasdaq
- Market Cap
- CZNC 312.9M
- ATYR 105.8M
- IPO Year
- CZNC N/A
- ATYR 2015
- Fundamental
- Price
- CZNC $19.47
- ATYR $0.98
- Analyst Decision
- CZNC
- ATYR Buy
- Analyst Count
- CZNC 0
- ATYR 6
- Target Price
- CZNC N/A
- ATYR $8.88
- AVG Volume (30 Days)
- CZNC 43.1K
- ATYR 11.2M
- Earning Date
- CZNC 10-17-2025
- ATYR 11-06-2025
- Dividend Yield
- CZNC 5.82%
- ATYR N/A
- EPS Growth
- CZNC 15.34
- ATYR N/A
- EPS
- CZNC 1.75
- ATYR N/A
- Revenue
- CZNC $108,310,000.00
- ATYR N/A
- Revenue This Year
- CZNC $5.72
- ATYR $420.85
- Revenue Next Year
- CZNC $7.18
- ATYR $1,513.40
- P/E Ratio
- CZNC $11.04
- ATYR N/A
- Revenue Growth
- CZNC 4.96
- ATYR N/A
- 52 Week Low
- CZNC $17.85
- ATYR $0.68
- 52 Week High
- CZNC $22.68
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- CZNC 48.14
- ATYR 31.66
- Support Level
- CZNC $18.95
- ATYR $0.96
- Resistance Level
- CZNC $19.52
- ATYR $1.07
- Average True Range (ATR)
- CZNC 0.31
- ATYR 0.09
- MACD
- CZNC -0.01
- ATYR 0.16
- Stochastic Oscillator
- CZNC 55.91
- ATYR 65.80
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.